Deborah Watkins Bruner, PhD, RN, FAAN, from the Nell Hodgson Woodruff School of Nursing at Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.
Deborah Watkins Bruner, PhD, RN, FAAN, professor, Nell Hodgson Woodruff School of Nursing, Emory University, discusses side effects associated with platinum-based drugs for the treatment of ovarian cancer.
FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers
March 22nd 2024Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.